These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21207168)

  • 1. Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.
    Krieger PM; Tamandl D; Herberger B; Faybik P; Fleischmann E; Maresch J; Gruenberger T
    Ann Surg Oncol; 2011 Jun; 18(6):1644-50. PubMed ID: 21207168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
    Huiskens J; van Gulik TM; van Lienden KP; Engelbrecht MR; Meijer GA; van Grieken NC; Schriek J; Keijser A; Mol L; Molenaar IQ; Verhoef C; de Jong KP; Dejong KH; Kazemier G; Ruers TM; de Wilt JH; van Tinteren H; Punt CJ
    BMC Cancer; 2015 May; 15():365. PubMed ID: 25943574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
    Wolf PS; Park JO; Bao F; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Kingham TP; Gönen M; Kemeny N; Shia J; D'Angelica MI
    J Am Coll Surg; 2013 Jan; 216(1):41-9. PubMed ID: 23041049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the usefulness of the indocyanine green clearance test for chemotherapy-associated liver injury in patients with colorectal cancer liver metastasis.
    Wakiya T; Kudo D; Toyoki Y; Ishido K; Kimura N; Narumi S; Kijima H; Hakamada K
    Ann Surg Oncol; 2014 Jan; 21(1):167-72. PubMed ID: 23959055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis.
    Takamoto T; Hashimoto T; Sano K; Maruyama Y; Inoue K; Ogata S; Takemura T; Kokudo N; Makuuchi M
    Ann Surg Oncol; 2010 Oct; 17(10):2747-55. PubMed ID: 20425145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients.
    Komori H; Beppu T; Baba Y; Horino K; Imsung C; Masuda T; Hayashi H; Okabe H; Ootao R; Watanabe M; Takamori H; Iyama K; Baba H
    Int J Clin Oncol; 2010 Jun; 15(3):263-70. PubMed ID: 20238233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
    Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
    Dede K; Láng I; Pörneczi B; Mester G; Fekete A; Kőszegi G; Mersich T; Besznyák I; Bursics A
    Magy Seb; 2013 Dec; 66(6):325-30. PubMed ID: 24333977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Choice of surgical strategy for colorectal liver metastases depending on clinical and pathological response to neoadjuvant chemo- and targeted therapy].
    Jakab F
    Orv Hetil; 2010 Nov; 151(47):1956-60. PubMed ID: 21071308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
    Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.
    Nakano H; Oussoultzoglou E; Rosso E; Casnedi S; Chenard-Neu MP; Dufour P; Bachellier P; Jaeck D
    Ann Surg; 2008 Jan; 247(1):118-24. PubMed ID: 18156931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
    Aussilhou B; Dokmak S; Faivre S; Paradis V; Vilgrain V; Belghiti J
    Ann Surg Oncol; 2009 Jun; 16(6):1553-9. PubMed ID: 19363584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.
    Dede K; Mersich T; Besznyák I; Zaránd A; Salamon F; Baranyai ZS; Landherr L; Jakab F; Bursics A
    Pathol Oncol Res; 2013 Jul; 19(3):501-8. PubMed ID: 23420304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HEMIHEPATECTOMY FOR RESECTABLE HEPATIC METASTASIS FROM COLORECTAL CANCER WITH POOR PROGNOSIS].
    Patyutko YI; Kotelnikov AG; Mamontov KG; Podluzhny DV; Ponomarenko AA
    Vopr Onkol; 2015; 61(3):439-47. PubMed ID: 26242159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences of chemotherapy on resection of colorectal liver metastases.
    Pessaux P; Chenard MP; Bachellier P; Jaeck D
    J Visc Surg; 2010 Aug; 147(4):e193-201. PubMed ID: 20655821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.
    Lubezky N; Winograd E; Papoulas M; Lahat G; Shacham-Shmueli E; Geva R; Nakache R; Klausner J; Ben-Haim M
    J Gastrointest Surg; 2013 Mar; 17(3):527-32. PubMed ID: 23299220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Liver resection after downstaging with neoadjuvant chemotherapy for "unresectable" colorectal metastases].
    Frena A; Martin F; La Guardia G; Vezzali N; Bonatti G; Stocker J; Graiff C
    Chir Ital; 2004; 56(3):351-7. PubMed ID: 15287631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
    Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB
    Oncology; 2013; 85(5):283-9. PubMed ID: 24217184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.